Intelligence desk

Products

Signal Tracker Data Platform Data Enrichment API

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Renovacor logo — Advancing transformative therapies for cardiovascular diseas...

Renovacor

Advancing transformative therapies for cardiovascular disease

Founded 2019 6 employees Post Ipo Equity Total: $41.00M Biotechnology, Health Care +1

General Information

Company Name Renovacor
Founded Year 2019
Founders / Decision Makers
Elizabeth (Beth) White — Chief Business Officer and SVP of Operations
Employees 6
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Post Ipo Equity
Social

Get notified when Renovacor moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Renovacor

Renovacor is a biotechnology company founded in 2013 with the slogan "Advancing transformative therapies for cardiovascular disease." The company is focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and related diseases. Renovacor's lead program in BAG3-associated dilated cardiomyopathy (DCM) utilizes gene transfer technology to address the monogenic cause of this severe form of heart failure. Their vision is to bring life-changing therapies to patients living with serious genetic cardiovascular and related diseases by developing medicines that target the underlying cause of the disease. Their last investment of $30.00MPost-IPO Equity was injected on 03 September 2021, involving a diverse group of investors including Innogest Capital, Acorn Bioventures, Affinity Asset Advisors, Altium Capital, Ikarian Capital, Longview Ventures, RTW Investments, 683 CAPITAL, Chardan, and Surveyor Capital. Renovacor operates in the Biotechnology and Health Care industries, demonstrating a commitment to addressing the critical unmet needs in cardiovascular health. With a strong focus on transformative benefit and significant improvement to the quality of life, Renovacor is poised to make an impact in the development of precision therapies for cardiovascular diseases.

Taxonomy: precision therapies, gene transfer technology, cardiovascular disease, gene therapy, dilated cardiomyopathy, BAG3 gene, preclinical-stage biopharmaceutical, recombinant adeno-associated virus (AAV), heart failure, orphan disease, genetic diseases, precision medicine, innovative therapies, transformational treatments

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $30.00M 10
Innogest Capital Acorn Bioventures Affinity Asset Advisors Altium Capital Ikarian Capital Longview Ventures RTW Investments 683 CAPITAL
Chardan, Surveyor Capital 		03 Sep 2021
Series A $11.00M - 15 Aug 2019

Renovacor Alternatives & Competitors

Renovacor vs
Taysha Gene Therapies
Taysha Gene Therapies United States

Taysha Gene Therapies is focused on advancing AAV-based gene therapies for severe monogenic diseases...

IPO
134 employees
Biotechnology, Life Sciences
Compare Renovacor vs Taysha Gene Therapies
Renovacor vs
Cartesian Therapeutics
Cartesian Therapeutics

Cartesian | Developing potent, safer cell and gene therapies for cancer and autoimmune diseases - Ca...

IPO
4 employees
Biotechnology
Renovacor vs
Tenaya Therapeutics
Tenaya Therapeutics United States

Scaling new heights in the fight against heart disease

Post Ipo Equity
93 employees
Biopharma, Biotechnology
Compare Renovacor vs Tenaya Therapeutics

FAQ About Renovacor

Advancing transformative therapies for cardiovascular disease
Renovacor was founded in 2019.
Renovacor operates in the following industries: Biotechnology, Health Care, Life Sciences.
Renovacor has approximately 6 employees.
Renovacor has completed 2 funding rounds, raising a total of $41.00M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Renovacor include Taysha Gene Therapies, Cartesian Therapeutics, Tenaya Therapeutics, Pharming Group N.V., Prevail Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Renovacor and Taysha Gene Therapies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Renovacor and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy